CY1114910T1 - Βιοδεικτης για παρακολουθηση ασθενων - Google Patents
Βιοδεικτης για παρακολουθηση ασθενωνInfo
- Publication number
- CY1114910T1 CY1114910T1 CY20141100110T CY141100110T CY1114910T1 CY 1114910 T1 CY1114910 T1 CY 1114910T1 CY 20141100110 T CY20141100110 T CY 20141100110T CY 141100110 T CY141100110 T CY 141100110T CY 1114910 T1 CY1114910 T1 CY 1114910T1
- Authority
- CY
- Cyprus
- Prior art keywords
- patient
- immunotherapy
- monitor
- monitoring
- methods
- Prior art date
Links
- 238000012544 monitoring process Methods 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305328 | 2009-04-17 | ||
| EP10719285.8A EP2419728B1 (en) | 2009-04-17 | 2010-04-12 | Biomarker for monitoring patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114910T1 true CY1114910T1 (el) | 2016-12-14 |
Family
ID=42270292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100110T CY1114910T1 (el) | 2009-04-17 | 2014-02-13 | Βιοδεικτης για παρακολουθηση ασθενων |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20120058493A1 (enExample) |
| EP (1) | EP2419728B1 (enExample) |
| JP (1) | JP5661738B2 (enExample) |
| KR (1) | KR20120027146A (enExample) |
| CN (1) | CN102395883B (enExample) |
| AU (1) | AU2010237215B2 (enExample) |
| BR (1) | BRPI1010512A2 (enExample) |
| CA (1) | CA2759050A1 (enExample) |
| CO (1) | CO6440591A2 (enExample) |
| CR (1) | CR20110513A (enExample) |
| CY (1) | CY1114910T1 (enExample) |
| DK (1) | DK2419728T3 (enExample) |
| ES (1) | ES2445146T3 (enExample) |
| HR (1) | HRP20140262T1 (enExample) |
| IL (1) | IL214917A (enExample) |
| MX (1) | MX2011010920A (enExample) |
| NZ (1) | NZ594896A (enExample) |
| PL (1) | PL2419728T3 (enExample) |
| PT (1) | PT2419728E (enExample) |
| RU (1) | RU2555340C2 (enExample) |
| SG (1) | SG175060A1 (enExample) |
| SI (1) | SI2419728T1 (enExample) |
| SM (1) | SMT201400046B (enExample) |
| TW (1) | TWI426270B (enExample) |
| WO (1) | WO2010119003A1 (enExample) |
| ZA (1) | ZA201107545B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013168550A1 (ja) * | 2012-05-11 | 2013-11-14 | 味の素株式会社 | 癌免疫療法の評価方法、癌免疫療法評価装置、癌免疫療法評価プログラム、癌免疫療法評価システムおよび情報通信端末装置 |
| US20140244556A1 (en) * | 2013-02-27 | 2014-08-28 | Abdul Saleh | Methods for and apparatus generating automated pharmaco genetics correlation |
| US20200353107A1 (en) * | 2017-12-08 | 2020-11-12 | Stc.Unm | In vivo imaging of tumor infiltration leukocytes |
| CN114859057A (zh) * | 2022-04-13 | 2022-08-05 | 江苏省中医院 | 人结直肠癌或人结直肠癌转移的预测性生物标志物及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| DE19520606B4 (de) | 1995-06-06 | 2004-04-08 | Roche Diagnostics Gmbh | Vorrichtung zur optischen Untersuchung von Oberflächen |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| EP0954593A1 (en) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| WO2000046355A2 (en) | 1999-02-04 | 2000-08-10 | Geron Corporation | Telomerase reverse transcriptase transcriptional regulatory sequences |
| FR2773885B1 (fr) | 1998-01-16 | 2000-03-03 | Elf Antar France | Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode |
| JP3119228B2 (ja) | 1998-01-20 | 2000-12-18 | 日本電気株式会社 | 液晶表示パネル及びその製造方法 |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| WO2001036650A2 (en) | 1999-11-15 | 2001-05-25 | Onyx Pharmaceuticals, Inc. | An oncolytic adenovirus |
| AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| WO2004011082A1 (en) | 2002-07-26 | 2004-02-05 | Myomend, Inc. | Cardiac rhythm management system with intramural myocardial pacing leads and electrodes |
| NZ540098A (en) | 2002-10-29 | 2008-09-26 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
| PT2366400E (pt) * | 2005-06-28 | 2016-02-02 | Oncothyreon Inc | Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1) |
| CA2668942A1 (en) * | 2006-12-05 | 2008-06-12 | Transgene S.A. | Means and method for raising improved immune response |
| RU2517719C2 (ru) * | 2008-05-29 | 2014-05-27 | Трансжене Са | Биомаркер для отбора пациентов и соответствующие способы |
-
2010
- 2010-04-12 BR BRPI1010512A patent/BRPI1010512A2/pt not_active IP Right Cessation
- 2010-04-12 AU AU2010237215A patent/AU2010237215B2/en not_active Ceased
- 2010-04-12 JP JP2012505138A patent/JP5661738B2/ja not_active Expired - Fee Related
- 2010-04-12 WO PCT/EP2010/054743 patent/WO2010119003A1/en not_active Ceased
- 2010-04-12 EP EP10719285.8A patent/EP2419728B1/en not_active Not-in-force
- 2010-04-12 KR KR1020117024190A patent/KR20120027146A/ko not_active Abandoned
- 2010-04-12 CA CA2759050A patent/CA2759050A1/en not_active Abandoned
- 2010-04-12 US US13/264,946 patent/US20120058493A1/en not_active Abandoned
- 2010-04-12 NZ NZ594896A patent/NZ594896A/xx not_active IP Right Cessation
- 2010-04-12 SG SG2011072360A patent/SG175060A1/en unknown
- 2010-04-12 CN CN201080016800.2A patent/CN102395883B/zh not_active Expired - Fee Related
- 2010-04-12 HR HRP20140262AT patent/HRP20140262T1/hr unknown
- 2010-04-12 SI SI201030533T patent/SI2419728T1/sl unknown
- 2010-04-12 RU RU2011146419/15A patent/RU2555340C2/ru not_active IP Right Cessation
- 2010-04-12 ES ES10719285.8T patent/ES2445146T3/es active Active
- 2010-04-12 PT PT107192858T patent/PT2419728E/pt unknown
- 2010-04-12 MX MX2011010920A patent/MX2011010920A/es active IP Right Grant
- 2010-04-12 DK DK10719285.8T patent/DK2419728T3/da active
- 2010-04-12 PL PL10719285T patent/PL2419728T3/pl unknown
- 2010-04-16 TW TW099112032A patent/TWI426270B/zh not_active IP Right Cessation
-
2011
- 2011-09-01 IL IL214917A patent/IL214917A/en not_active IP Right Cessation
- 2011-09-29 CR CR20110513A patent/CR20110513A/es unknown
- 2011-10-14 ZA ZA2011/07545A patent/ZA201107545B/en unknown
- 2011-10-14 CO CO11136970A patent/CO6440591A2/es not_active Application Discontinuation
-
2014
- 2014-01-08 US US14/150,503 patent/US20140141039A1/en not_active Abandoned
- 2014-02-13 CY CY20141100110T patent/CY1114910T1/el unknown
- 2014-04-03 SM SM201400046T patent/SMT201400046B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121872T1 (el) | Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| WO2018089693A3 (en) | Methods for determining and monitoring gastrointestinal inflammation | |
| CY1123172T1 (el) | Δοκιμασια για συλληψη και ανιχνευση κυκλοφορουντων κυτταρων πολλαπλου μυελωματος απο αιμα | |
| AR088827A1 (es) | Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer | |
| BR112013013460A8 (pt) | métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| CY1119262T1 (el) | Αναλυτικες μεθοδοι και συστοιχιες για χρηση στην ταυτοποιηση παραγοντων που επαγουν ευαισθητοποιηση στο ανθρωπινο δερμα | |
| TR201907241T4 (tr) | IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. | |
| GB201305223D0 (en) | Reflection detection type measurement apparatus for skin autofluorescence | |
| MX343327B (es) | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. | |
| MX2010005244A (es) | Composiciones y métodos para la terapia y el diagnóstico de influenza. | |
| CY1116089T1 (el) | Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων | |
| MX368099B (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| CY1115437T1 (el) | Υδροξυμεθυλοκυκλοεξυλαμινες | |
| CY1115566T1 (el) | Παραγωγα phenoxypyridinyl amide και η χρηση τους στην θεραπεια καταστασεων ασθενειας με την μεσολαβηση της pde4 | |
| MX2012003997A (es) | Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2. | |
| MX386919B (es) | Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. | |
| BR112013024213B8 (pt) | Método de fabricação de instrumento médico e instrumento médico | |
| MX377026B (es) | Biomarcadores para la progresión de enfermedades en melanoma. | |
| CY1122474T1 (el) | Μεθοδος διαγνωσης νευραλγιας του τριδυμου | |
| BR112015021507A2 (pt) | métodos e composições para o diagnóstico de pré-eclampsia | |
| CY1121406T1 (el) | Διαγνωση καρδιακης ανεπαρκειας | |
| MX2015001788A (es) | Metabolitos de metionina predicen la evolución agresiva del cáncer. | |
| BR112013027851A2 (pt) | métodos para identificar um indivíduo caucasiano e para determinar uma suscetibilidade do indivíduo caucasiano de ter ou desenvolver a degeneração macular relacionada com a idade, e, kit |